Pfizer (PFE) Outperforms Broader Market: What You Need to Know

In the latest trading session, Pfizer (PFE) closed at $25.90, marking a +1.49% move from the previous day. The stock's change was more than the S&P 500's daily gain of 1.16%. Elsewhere, the Dow gained 1.21%, while the tech-heavy Nasdaq added 1.18%. The drugmaker's stock has climbed by 2.57% in the past month, exceeding the Medical sector's loss of 1.32% and the S&P 500's loss of 0.42%.Market participants will be closely following the financial results of Pfizer in its upcoming release. The company plans to announce its earnings on February 3, 2026. The company is forecasted to report an EPS of $0.58, showcasing a 7.94% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $16.84 billion, indicating a 5.19% decrease compared to the same quarter of the previous year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.14 per share and a revenue of $61.89 billion, signifying shifts of +0.96% and 0%, respectively, from the last year. It's also important for investors to be aware of any recent modifications to analyst estimates for Pfizer. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.06% lower within the past month. Pfizer currently has a Zacks Rank of #4 (Sell). Investors should also note Pfizer's current valuation metrics, including its Forward P/E ratio of 8.51. This signifies a discount in comparison to the average Forward P/E of 14.81 for its industry. The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 100, positioning it in the top 41% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks